GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$37.56 USD
+0.41 (1.10%)
Updated Aug 1, 2025 03:59 PM ET
After-Market: $37.55 -0.01 (-0.03%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GSK 37.56 +0.41(1.10%)
Will GSK be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GSK
Company News for Jul 31, 2025
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK (GSK) Q2 Earnings and Revenues Beat Estimates
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth
Other News for GSK
Notable healthcare headlines for the week: Trump’s ultimatum to big pharma, Novo Nordisk, UnitedHealth and Moderna in focus
Market Voices: Trump vs. Big Pharma, Swiss tariffs, tariff legality
Experts helping vaccine advisors are reportedly ousted at CDC
Trump Trade: Trump signs executive order raising tariff on Canada to 35%
European pharmaceutical stocks slip after Trump pushes for lower drug prices